New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

被引:494
作者
Palmer, S
Wiegand, AP
Maldarelli, F
Bazmi, H
Mican, JM
Polis, M
Dewar, RL
Planta, A
Liu, SY
Metcalf, JA
Mellors, JW
Coffin, JM
机构
[1] NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JCM.41.10.4531-4536.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
More sensitive assays for human immunodeficiency virus type 1 (HIV-1) RNA are needed to detect, quantify, and characterize persistent viremia in patients who are receiving antiretroviral therapy and whose plasma HIV-1 RNA levels are suppressed to less than 50 to 75 copies/ml. We therefore developed an internally controlled real-time reverse transcriptase-initiated PCR assay that quantifies HIV-1 RNA concentrations down to 1 copy per ml of plasma. This assay with single-copy sensitivity (the single-copy assay) generates a reproducible linear regression plot of input copy number versus threshold cycle by using HIV-1 RNA transcripts at copy numbers ranging from 1 to 106 per reaction mixture. The single-copy assay was compared to the ultrasensitive AMPLICOR HIV-1 MONITOR assay and a more sensitive modification of the ultrasensitive assay by repeatedly testing a low-copy-number panel containing 200 to 0.781 copies of HIV-1 RNA per ml of plasma. This comparison showed that the single-copy assay had a greater sensitivity than the other assays and was the only assay that detected HIV-1 RNA at levels as low as 0.781 copies/ml. Testing of plasma samples from 15 patients who were receiving antiretroviral therapy and who had <75 HIV-1 RNA copies/ml revealed persistent viremia in all 15 patients, with HIV-1 RNA levels ranging from 1 to 32 copies/ml (median, 13 copies/ml). The greater sensitivity of the single-copy assay should allow better characterization of persistent viremia in patients who are receiving antiretroviral therapy and whose HIV-1 RNA levels are suppressed to below the detection limits of present assays.
引用
收藏
页码:4531 / 4536
页数:6
相关论文
共 32 条
[1]   Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J].
Chun, TW ;
Stuyver, L ;
Mizell, SB ;
Ehler, LA ;
Mican, JAM ;
Baseler, M ;
Lloyd, AL ;
Nowak, MA ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13193-13197
[2]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[3]   A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml [J].
Collins, ML ;
Irvine, B ;
Tyner, D ;
Fine, E ;
Zayati, C ;
Chang, CA ;
Horn, T ;
Ahle, D ;
Detmer, J ;
Shen, LP ;
Kolberg, J ;
Bushnell, S ;
Urdea, MS ;
Ho, DD .
NUCLEIC ACIDS RESEARCH, 1997, 25 (15) :2979-2984
[4]   Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy [J].
Dornadula, G ;
Zhang, H ;
VanUitert, B ;
Stern, J ;
Livornese, L ;
Ingerman, MJ ;
Witek, J ;
Kedanis, RJ ;
Natkin, J ;
DeSimone, J ;
Pomerantz, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (17) :1627-1632
[5]   Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5 [J].
Elbeik, T ;
Charlebois, E ;
Nassos, P ;
Kahn, J ;
Hecht, FM ;
Yajko, D ;
Ng, V ;
Hadley, K .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (03) :1113-1120
[6]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[7]   Prevalence and predictive value of intermittent viremia with combination HIV therapy [J].
Havlir, DV ;
Bassett, R ;
Levitan, D ;
Gilbert, P ;
Tebas, P ;
Collier, AC ;
Hirsch, MS ;
Ignacio, C ;
Condra, J ;
Günthard, HF ;
Richman, DD ;
Wong, JK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :171-179
[8]   RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].
HO, DD ;
NEUMANN, AU ;
PERELSON, AS ;
CHEN, W ;
LEONARD, JM ;
MARKOWITZ, M .
NATURE, 1995, 373 (6510) :123-126
[9]   Monitoring plasma HIV-1 RNA levels in addition to CD4(+) lymphocyte count improves assessment of antiretroviral therapeutic response [J].
Hughes, MD ;
Johnson, VA ;
Hirsch, MS ;
Bremer, JW ;
Elbeik, T ;
Erice, A ;
Kuritzkes, DR ;
Scott, WA ;
Spector, SA ;
Basgoz, N ;
Fischl, MA ;
DAquila, RT .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) :929-938
[10]   ADAPTER PLASMIDS SIMPLIFY THE INSERTION OF FOREIGN DNA INTO HELPER-INDEPENDENT RETROVIRAL VECTORS [J].
HUGHES, SH ;
GREENHOUSE, JJ ;
PETROPOULOS, CJ ;
SUTRAVE, P .
JOURNAL OF VIROLOGY, 1987, 61 (10) :3004-3012